Breaking News

Fresenius Expands Biosimilars Portfolio with Denosumab Biosimilars in the U.S.

The U.S. launch of Conexxence and Bomyntra follows the FDA’s approval in March 2025.

By: Rachel Klemovitch

Assistant Editor

Fresenius announced that its operating company, Fresenius Kabi, has introduced two new biosimilars – Conexxence (denosumab-bnht) and Bomyntra (denosumab-bnht) – in the United States. These denosumab biosimilars are approved by the FDA for all indications of the reference products: Prolia (denosumab) and Xgeva (denosumab), respectively. Conexxence (denosumab-bnht) is approved for use in various adult patient populations at high risk for fractures, including individuals with oste...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters